These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 3875310)

  • 21. Increased beta-lactamase activity in Branhamella catarrhalis after exposure to amoxicillin and clavulanic acid.
    Bedenić B; Zagar Z
    J Chemother; 1994 Dec; 6(6):383-7. PubMed ID: 7699424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of beta-lactamases in the response of pulmonary infections to amoxycillin/clavulanate.
    Stockley RA; Dragicevic P; Burnett D; Hill SL
    J Antimicrob Chemother; 1989 Nov; 24 Suppl B():73-81. PubMed ID: 2606821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections.
    Hoban D; Felmingham D
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():49-59. PubMed ID: 12239228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis.
    Doern GV
    Diagn Microbiol Infect Dis; 1991; 14(1):75-7. PubMed ID: 1901536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
    Dere WH; Farlow D; Therasse DG; Jacobson KD; Guerra FJ
    Clin Ther; 1992; 14(2):166-77. PubMed ID: 1611641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination.
    Stein GE; Gurwith MJ
    Clin Pharm; 1984; 3(6):591-9. PubMed ID: 6391783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
    Pal RB; Pal P; Jain S; Kulkarni KP
    J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections.
    Hoepelman AI; Sips AP; van Helmond JL; van Barneveld PW; Neve AJ; Zwinkels M; Rozenberg-Arska M; Verhoef J
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():147-52. PubMed ID: 8396086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with secondary bacterial infections of acute bronchitis.
    Henry D; Ruoff GE; Rhudy J; Puopolo A; Drehobl M; Schoenberger J; Giguere G; Collins JJ
    Clin Ther; 1995; 17(5):861-74. PubMed ID: 8595638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Branhamella catarrhalis: incidence in pulmonary infections and determination of sensitivity to 5 antibiotics].
    Texier-Maugein J; Escoubas J; Fouche J; Mormede M
    Pathol Biol (Paris); 1988 May; 36(5):540-3. PubMed ID: 3136431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
    J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
    Blandino G; Aleo G; Caccamo F; Nicolosi VM; Siracusa V; Speciale A
    J Chemother; 1996 Jun; 8(3):193-9. PubMed ID: 8808715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
    Bogdanovich T; Clark C; Ednie L; Lin G; Smith K; Shapiro S; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2050-7. PubMed ID: 16723565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.
    Doern GV; Brueggemann AB; Pierce G; Holley HP; Rauch A
    Antimicrob Agents Chemother; 1997 Feb; 41(2):292-7. PubMed ID: 9021182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory tract infections caused by beta-lactamase producing organisms treated with augmentin.
    Mehtar S
    Scott Med J; 1982; 27 Spec No.():S24-7. PubMed ID: 6984777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
    Blondeau JM; Vaughan D; Laskowski R; Borsos S;
    Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative trial of cefprozil vs. amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion.
    Arguedas AG; Zaleska M; Stutman HR; Blumer JL; Hains CS
    Pediatr Infect Dis J; 1991 May; 10(5):375-80. PubMed ID: 1906160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.